Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2013

View Archived Issues

Phase III study of GSK-2132231A in melanoma misses first co-primary endpoint

Novartis enters into global licensing and research collaboration with Regenerex

Novartis presents new series of USP2 inhibitors

New mouse model mimics hyperargininemia

Novel TYK2 inhibitors divulged by Takeda Pharmaceuticals

iPierian secures financing to launch spin-out company

Panax ginseng extract prevents adverse cisplatin effects in vivo

New locked nucleic acid antisense oligonucleotides disclosed by U.S. team

Blood smear filipin staining speeds NP-C diagnosis

Lilly presents new mGlu2 positive allosteric modulator for the treatment of anxiety

Novel tricyclic IAP antagonists synthesized at Takeda

FDA accepts corifollitropin alfa NDA for review

Merck KGaA divulges novel protein kinase inhibitors

Oncolytics Biotech reports final tumor response data for phase II study of Reolysin

Bayer Intellectual Property patents new FGFR inhibitors

Neuren Pharmaceuticals cleared to conduct phase II NNZ-2566 trial

Debiopharm and TCG Lifesciences to develop a novel class of antibiotics

Spanish team prepares novel sigma1 receptor ligands

Chimerix begins phase III trial of brincidofovir

BL-8040 receives FDA orphan drug designation for treatment of AML

Gamida Cell reports transplantation of first patient in phase I/II study of NiCord in blood cancers

Aegerion obtains orphan drug designation in Japan for use of lomitapide in treatment of HoFH

Stem Cell Therapeutics to initiate IND-enabling program for CD47 antagonist

FDA grants orphan status to ublituximab for two non-Hodgkin's lymphoma subtypes

Neurocrine discloses results from phase IIb trial of NBI-98854 for treatment of tardive dyskinesia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.